Euthyrox

ApprovedSmall molecule

MMaastricht University Medical Center

Euthyrox is one of 72 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Intracerebral HemorrhageActive, not recruiting

Type 2 Diabetes MellitusApproved

Active, not recruiting

Intracerebral HemorrhagePreclinical

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Euthyrox

MMaastricht University Medical Center

Approved

1 2

Byetta

AstraZeneca

Preclinical

20 3

Tanzeum

GSK

Preclinical

10 4

Insulin 320

Novo Nordisk

Preclinical

43 5

Adenocard

Astellas

Preclinical

1 6

NOVOLIN R

Novo Nordisk

Preclinical

1 7

Dostinex

Cipro

Lantus

6 10

Glargine

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Not yet recruiting

Efficacy

NCT06647602

Clinical

Trials by Indication[1]

Intracerebral Hemorrhage1 trial

Efficacy of Thyroid Hormone Replacement for Secondary Hypothyroidism Following Intracerebral Hemorrhage

Recruiting·PPeking Union Medical College Hospital·N/A·NCT06353555·100 enrolled

Type 2 Diabetes Mellitus1 trial

Thyroid Study Type 2 Diabetes Mellitus (T2DM)

Unknown status·MMaastricht University Medical Center·Phase 4·NCT01379170·17 enrolled

Efficacy1 trial

Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy

Not yet recruiting·UUniversity Medical Center Groningen··NCT06647602·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Euthyrox. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Euthyrox compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Euthyrox. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Maastricht University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMaastricht University Medical Center

Euthyrox

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Intracerebral Hemorrhage1 trial

Type 2 Diabetes Mellitus1 trial

Efficacy1 trial

References

Drug Info

Quick Facts

Related News